TRUST-II: A global phase II study for taletrectinib in <i>ROS1</i> fusion–positive lung cancer and other solid tumors.
Misako Nagasaka(University of California, Irvine), Yuichiro Ohe(National Cancer Center), Tatsuro Okamoto(National Hospital Organization Kyushu Cancer Center), Luis E. Raez(Florida International University), Noriko Yanagitani(The Cancer Institute Hospital), Toshiaki Takahashi(Okayama University), Hidetoshi Hayashi(Kindai University), Chang‐Min Choi(Ulsan College), Kaname Nosaki(National Cancer Center Hospital East), John Khoury(Oakland University), Yutaka Fujiwara(Aichi Cancer Center), Jorge J. Nieva(University of Southern California), Anastasios Dimou(Mayo Clinic), Shunichi Sugawara(Sendai Kousei Hospital), Sai‐Hong Ignatius Ou(University of California, Irvine Medical Center), Geoffrey Liu(Princess Margaret Cancer Centre), Hongbin Chen(Peking University), Nathan A. Pennell(Cleveland Clinic), Takashi Seto(National Hospital Organization Kyushu Cancer Center), Afshin Eli Gabayan(Beverly Hills Cancer Center)
Cited by 4
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Alectinib versus Crizotinib in Untreated <i>ALK</i>-Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2017|2.4k
Crizotinib in <i>ROS1</i>-Rearranged Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2014|2k